FRANKLIN, Mass., Jan. 8 /PRNewswire-FirstCall/ -- Sontra Medical Corporation announced today that in connection with its previously announced decision to voluntarily delist from the Nasdaq Capital Market, on January 8, 2007, Nasdaq suspended the quotation of Sontra’s common stock. Although the quotation of Sontra’s common stock has been suspended, Sontra will remain subject to Nasdaq rules until its delisting is effective on January 18, 2007.
As of January 8, 2007, the Company’s quotation for its common stock is expected to appear in the “Pink Sheets” under the symbol “SONT.” The Company’s common stock may also be quoted in the future on the OTC Bulletin Board provided a market maker files the necessary application with the NASD and such application is cleared. Following its delisting from Nasdaq, the Company expects to remain a public company and to continue to make its required SEC filings.
About Sontra Medical Corporation (http://www.sontra.com)
Sontra Medical Corporation, a technology leader in transdermal science, has been developing a non-invasive, continuous transdermal glucose monitor (“CTGM”) for principal use in the Intensive Care Market. In addition, the Company owns a platform technology, the SonoPrep(R) Permeation System, and other technology for transdermal delivery of large molecule drugs and vaccines.
SonoPrep is a registered trademark of Sontra Medical Corporation. All other company, product or service names mentioned herein are the trademarks or registered trademarks of their respective owners.
Investor Relations Contacts: Harry G. Mitchell, Interim CEO 508-530-0311 hmitchell@sontra.com
Sontra Medical Corporation
CONTACT: Harry G. Mitchell, Interim CEO of Sontra Medical Corporation,+1-508-530-0311, or hmitchell@sontra.com
Web site: http://www.sontra.com/
